PRE-MARKET | November 04, 2016 | $FEYE, $UBNT, $EXEL, $LVS, $FB, $WYNN, $GPRO, $CBS, $SBUX, $HLF, #traders

PRE-MARKET | November 04, 2016 | $FEYE, $UBNT, $EXEL, $LVS, $FB, $WYNN, $GPRO, $CBS, $SBUX, $HLF, #traders

PRE-MARKET MOVERS

 

UPGRADES

8. JUNO:$JUNO Upgraded to Neutral at BTIG Research
10. TRUE:$TRUE upgraded at Stephens, Craig, and Loop Capital. 3 upgrades

 

DOWNGRADES

8. FIT:$FIT downgraded to Equal-Weight at Barclays – PT cut $10 from $24, downgraded to Neutral at Wedbush – PT cut $10 from $18
13. TEVA:$TEVA downgraded to Hold at HSBC
15. WFM:$WFM downgraded to Underperform at Bank of America

 

EARNINGS

 

Trending Social Alerts

 

Trending News Headlines

1. Apple is taking 104% of the profits in the entire smartphone industry

It sounds impossible — but no other company in the smartphone business comes even remotely close to Apple’s success.

2. Exclusive: Saudis threaten to raise oil output again as sparring with Iran returns

By Rania El Gamal and Alex Lawler DUBAI/LONDON (Reuters) – Old disputes between Saudi Arabia and rival Iran resurfaced at a meeting of OPEC experts last week, with Riyadh threatening to raise…

3. Skyworks Solutions (SWKS) PT, Estimates Lifted at Needham & Company; Consistent Execution

Needham & Company analyst N. Quinn Bolton reiterated a Buy rating and boosted his price target on Skyworks Solutions (NASDAQ: SWKS) to $84.00 (from $73.00) following results. The firm notes consistent execution and…

4. Payrolls in U.S. Rose by 161,000 in October as Wages Accelerate

U.S. jobs continued to gain at a steady pace in October and wage gains accelerated, signs that the labor market and economy made steady progress at the start of the fourth quarter.

Technology News

PRE-MARKET | November 03, 2016 | $FB, $WYNN, #FOMC, $USO, $CL_F, $ES_F, $WFM, $MET, $AIG, $ADBE, $CYBR

PRE-MARKET | November 03, 2016 | $FB, $WYNN, #FOMC, $USO, $CL_F, $ES_F, $WFM, $MET, $AIG, $ADBE, $CYBR

PRE-MARKET MOVERS

 

UPGRADES

6. RIG:$RIG upgraded to Buy at Canaccord Genuity
7. X:$X upgraded to Neutral at Bank of America

 

DOWNGRADES

2. EL:$EL downgraded to Underperform at CLSA
3. FIT:BofA does the ol’ buy-to-sell downgrade on $FIT. @CNBC
7. SKX:$SKX downgraded to Neutral at B. Riley

 

EARNINGS

 

Trending Social Alerts

1. FIT:LIVE NOW: $FB’s slowing growth, $FIT’s flop and a shake-up at $WFM – Watch our stocks preview…
4. GBPUSD:Govt loses! $GBPUSD surging
7. CWEI:@Orangeman1992 I’ll tell ya one thing : $CWEI priced for much higher oil , not a return < $40 . That record says a lot
8. DDD:3D Systems Reports Q3 Adj. EPS $0.14 vs $0.09 Est., Sales $156.4M vs $160M Est. $DDD

 

Trending News Headlines

1. Paper: Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia: Update from the Northstar Hgb-204 Phase 1/2 Clinical Study

Alexis A. Thompson, MD, MPH 1 , Janet Kwiatkowski, MD 2 , John Rasko, MBBS, PhD 3 , Suradej Hongeng, MD 4 * , Gary J. Schiller, MD 5 , Usanarat Anurathapan, MD 4 * , Marina Cavazzana, MD, PhD 6 , P. Joy Ho 3 , Christof von Kalle, MD 7 * , Morris Kletzel, MD, FAAP, MBA 8 , Philippe Leboulch, MD 4,9,10 * , Elliott Vichinsky, MD 11 , Alexandria Petrusich 12 * , Mohammed Asmal, MD, PhD 12 * and Mark C. Walters, MD 13

2. While 5,000 Wells Fargo Employees Got Fired, Their Bosses Thrived

After Wells Fargo & Co. executive John Sotoodeh handed off more than a hundred branches in Southern California to a colleague in 2009, problems surfaced quickly.

3. Paper: A Phase 1 Study of TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Stephen Ansell, MD, PhD 1 , Robert W Chen, MD 2 , Ian W. Flinn, MD, PhD 3 , Michael B. Maris, MD 4 , Owen A. O’Connor, MD, PhD 5 , Lisa DS Johnson, PhD 6 * , Meghan Irwin 6 * , Penka S. Petrova, PhD 6 * , Robert A. Uger, PhD 7 * and Eric L Sievers, MD 6

4. Hillary Clinton Still Leads a Tighter Race, Times/CBS News Poll Shows

Most voters say that their minds are made up and that late revelations about Mrs. Clinton and Donald J. Trump made no significant difference to them.

5. Wells Fargo Confirms SEC Probe Into Its Sales Practices

Wells Fargo confirmed that the Securities and Exchange Commission is one of the agencies probing matters related to its sales practices.

6. Inside Wells Fargo, workers say the mood is grim

Wells Fargo workers tell CNNMoney they are angry at the bank for shifting blame on them and remain scared of being retaliated against for speaking up about bad behavior.

7. New Goldman ETF tracks popular hedge fund stock bets

Goldman Sachs Group Inc has launched a new exchange traded fund that mimics the most popular stock bets made by hedge funds, the bank said on Thursday.

8. Trillium Therapeutics Announces Investor and Scientific Presentation Schedule for Remainder of 2016

TORONTO, Nov. 3, 2016 — Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR) , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is scheduled to present an update on the company’s programs and progress at several upcoming conferences in 2016. Investor Conference: Oppenheimer Life Sciences Summit Attendee: Niclas Stiernholm, PhD, Trillium Chief Executive Officer Date and Time: Nov. 29, 2016 Location: Sofitel Hotel, New York City Scientific Conferences: The Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting Presenter: Lisa Johnson, PhD, Trillium Research Scientist Title: CD47 is Overexpressed on Merkel Cell Carcinoma and a Target for SIRPαFc Therapy Date and Time: Nov. 11, 2016, 12:15 – 1:30 p.m. and 6:15 – 7:30 p.m. ET Location: Gaylord National Hotel Convention Center, National Harbor, MD American Society of Hematology (ASH) 58th Annual Meeting Presenter: Stephen Ansell, MD, Division of Hematology,

Technology News

PRE-MARKET | November 02, 2016 | $BABA, $TWX, $FB, $FIT, $XOM, $QCOM, $YELP, $SPX, $TLT, $ES_F, #earnings #FOMC #Traders

PRE-MARKET | November 02, 2016 | $BABA, $TWX, $FB, $FIT, $XOM, $QCOM, $YELP, $SPX, $TLT, $ES_F, #earnings #FOMC #Traders

PRE-MARKET MOVERS

 

UPGRADES

2. GILD:$GILD upgraded to Outperform at BMO Capital

 

DOWNGRADES

6. ILMN:$ILMN downgraded to Underweight at First Analysis
8. PFE:$PFE downgraded to Hold at Argus, downgraded to Market Perform at BMO Capital

 

EARNINGS

 

Trending Social Alerts

1. ANTM:$ANTM CEO Swedish on #Obamacare reforms: extend Cadillac Tax freeze, extend risk adjustment, flexibility on products, tighten grace period.
3. AGN:$AGN Announces $10 Billion Accelerated Share Repurchase, Initiation of Cash Dividend in 2017
4. BRCD:Broadcom to acquire Brocade Communications in $5.9B deal • $BRCD $AVGO
9. TWX:Time Warner Reports Q3 Adj. EPS $1.83 vs $1.37 Est., Sales $7.2B vs $7B Est. $TWX
11. BABA:$BABA Alibaba Q3 16 Earnings Results: -Adj EPS: $0.79 -Revenue: $5.1B

 

Trending News Headlines

1. Gilead was great once but is now awful and depressing

I want the old Gilead back! The present Gilead, with a stock down 27% for the year, trading at levels not seen since April 2014, is too sad to bear.

2. Andy Biotech on Twitter

“$CEMP — Long list of safety/pharmacokinetic/efficacy issues that FDA identified”

3. Andy Biotech on Twitter

“$CEMP — FDA: “We conclude that these findings comprise a genuine liver injury signal. “”

4. Briefing Information for the November 4, 2016 Meeting of the Antimicrobial Drugs Advisory Committee (AMDAC)

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance

5. 2016 Meeting Materials, Antimicrobial Drugs Advisory Committee (formerly known as the Anti-Infective Drugs Advisory Committee)

Page Last Updated: 11/02/2016 Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players . Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English

6. Palatin female libido-boosting shot fails crucial sex frequency test

Palatin appears be to playing a game of bait and switch with the design of its phase III studies.

7. Alibaba Jumps On Q3 Earnings Beat; Cloud Loss Narrowed

Alibaba Group (BABA) jumped 3.6% in pre-market after reporting better-than-expected third-quarter earnings. Revenue at Alibaba grew 55% from a year ago to 34.29 billion yuan, broadly in line with the 54% growth predicted by the street. But earnings per share came in at 5.26 yuan ($0.79), well above street estimate of 4.69 yuan, or $0.69. […]

8. Andy Biotech on Twitter

“$CEMP — As expected, liver tox is the key focus of solithromycin safety issues”

9. U.S. Steel Cuts Annual View, Posts Third-Quarter Profit

U.S. Steel Corp. lowered its full-year guidance as it continues to recover from unplanned outages in the third quarter and invest in additional maintenance spending. The company posted a third-quarter profit.

10. Gilead Quarterly Profit Misses on Low Hepatitis C Drug Sales

Gilead Sciences Inc. posted third-quarter profit that missed analysts’ estimates amid steadily declining sales of its hepatitis C drugs, though it isn’t rushing to fill its pipeline with deals.

11. zach on Twitter

“yikes $CEMP”

12. Yelp shares jump after company reports surprise profit

By

13. Private companies created fewer jobs than expected in October as pace of growth slows

ADP also revised job creation numbers for other months as part of a new measuring model.

14. Chipmaker Broadcom to buy network gear maker Brocade for $5.5 billion

Chipmaker Broadcom Ltd (AVGO.O) said on Wednesday it would buy network gear maker Brocade Communications Systems Inc (BRCD.O) for $5.5 billion in cash, to expand its fiber channel and data storage businesses.

15. Allergan expands buyback to $15 billion, sets first quarterly dividend

Allergan Plc (AGN.N) on Wednesday expanded its share buyback program by $5 billion to $15 billion and set its first-ever quarterly dividend, cushioning the impact of lower-than-expected quarterly revenue and lifting its shares.

Technology News

PRE-MARKET | November 01, 2016 | $BP, $CMG, $CVX, $GILD, $X, $CMI, $TAP, $HLF, $COH, $PFE, $ICE #traders, #options

PRE-MARKET | November 01, 2016 | $BP, $CMG, $CVX, $GILD, $X, $CMI, $TAP, $HLF, $COH, $PFE, $ICE #traders, #options

PRE-MARKET MOVERS

 

UPGRADES

2. CVX:$CVX upgraded to Overweight at Morgan Stanley – PT raise $130 from $113

 

DOWNGRADES

1. BHI:$BHI downgraded to Outperform at Raymond James

 

EARNINGS

 

Trending Social Alerts

1. PFE:$PFE discontinues development of its PCSK9 inhibitor.
4. BHI:$BHI downgraded to Outperform at Raymond James
5. BABA:surprised Ackman isn’t long $BABA, has accounting irregularities, whistle-blowers and SEC investigations
6. COH:Coach Q1 EPS $0.45 vs $0.45 Est, Revenue $1.04B vs $1.07B Est. $COH
8. SHPG:$SHPG terminates SHP610 after Ph2b study did not meet primary endpoint of slowing cognitive decline in pts with early stage #Sanfilippo A.

 

Trending News Headlines

1. ‘High-up’ Alibaba staffer helping SEC probe into tech giant

A federal probe of Alibaba’s books is far from dead — and it’s getting help from at least one insider. The Securities and Exchange Commission is working with one or more whistleblowers as it invest…

2. Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor | Pfizer: One of the world’s premier biopharmaceutical companies

Pfizer Inc. announced today the discontinuation of the global clinical development program for bococizumab, its investigational Proprotein Convertase Subtilisin Kexin type 9 inhibitor (PCSK9i). The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for lipid-lowering agents, indicates that bococizumab is not likely to provide value to patients, physicians, or shareholders. As a result, Pfizer has decided to discontinue the development program, including the two ongoing cardiovascular outcome studies.

3. Pfizer Cuts Outlook, Ends Development of Cholesterol Drug

Pfizer Inc. on Tuesday lowered its earnings outlook for the year and said it was ending the development of a drug in the massive cholesterol-treatment sector.

4. Pfizer profit just misses; company scraps cholesterol drug

Pfizer Inc (PFE.N), the largest U.S. drugmaker, reported a quarterly adjusted profit that just missed analysts’ estimates, and the company shaved 4 cents off its 2016 earnings forecast after scrapping development of a cholesterol-lowering treatment.

5. Gannett ends talks to buy Tronc

This story is developing. Please check back for further updates.

6. Gannett Abandons Its Attempt to Buy Tronc

Newspaper company Gannett has dropped its bid to buy Chicago Tribune publisher Tronc, ending a monthslong pursuit of its rival.

7. Tronc is crashing after Gannett terminates buyout talks

The owner of the USA Today is not buying the owner of the Chicago Tribune and the stocks are crashing.

8. Gannett Abandons Effort to Buy Newspaper Publisher Tronc

Investor expectations will now present tough questions for the former Tribune Publishing, owner of The Los Angeles Times and Chicago Tribune.

9. SAP Ariba Celebrates Two Decades of Procurement Innovation

Twenty years ago, procurement was a manual function driven largely by phone calls, faxes and handshakes. Then along came the Internet. And a company n

10. Drugmaker Sanofi hungry for deals after earnings beat

French drugmaker Sanofi stepped up its overhaul on Friday, putting its European generic drugs business up for sale and saying that a planned 3.5 billion euro ($3.8 billion) share buyback would not suppress its appetite for deals.

11. Press Release | Investor Relations | Ionis Pharmaceuticals

CARLSBAD, Calif. , Nov. 1, 2016 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced positive data from a Phase 2 placebo-controlled study evaluating IONIS-FXI Rx in patients with end-stage renal disease (ESRD) on hemodialysis. In this Phase 2 study patients treated with IONIS-FXI Rx achieved statistically significant, dose-dependent reductions in Factor XI activity. There were no clinically meaningful reductions in platelet levels and no treatment-related major or clinically relevant non-major bleeding events.

Technology News

PRE-MARKET | October 31, 2016 | $CVX, $AAPL, $CHKP, $MACK, $QCOM, $POT, $TEVA, $BIDU, $LOW, #Halloween #traders

PRE-MARKET | October 31, 2016 | $CVX, $AAPL, $CHKP, $MACK, $QCOM, $POT, $TEVA, $BIDU, $LOW, #Halloween #traders

PRE-MARKET MOVERS

 

UPGRADES

3. AGN, HZNP, TEVA:Mizuho cut $hznp PT ahead of earnings. CS upgrades $teva to outperform. Barclays reiterates = weight for $agn.
8. CVX:$CVX upgraded to Buy at Goldman Sachs
9. DE:$DE upgraded to Outperform at Baird
13. INVA:$inva upgraded to outperform by Cowen.
20. QCOM:$QCOM upgraded to Buy at Nomura
23. TEVA:$TEVA upgraded to Outperform at Credit Suisse – PT cut $52 from $59

 

DOWNGRADES

3. BIDU:$BIDU downgraded to Neutral at Macquarie
7. HD:$HD downgraded to neutral at PiperJaffray
13. NKE:$NKE downgraded to Underperform at Bank of America
16. XOM:$XOM downgraded to Neutral at GoldmanSachs

 

EARNINGS

 

Trending Social Alerts

1. ARIA:$ARIA – brigatinib PDUFA April 29, 2017.
4. CAH:$CAH Cardinal Health Q1 17 Earnings Results: -Adj EPS: $1.24 -Revenue: $32B

 

Trending News Headlines

1. GE to Combine Oil and Gas Business With Baker Hughes

General Electric reached a deal to combine its oil-and-gas business with Baker Hughes, creating a publicly traded energy powerhouse that would give GE a cost-effective way to play any recovery in the industry.

2. Bauer ice hockey gear maker files bankruptcy in U.S. and Canada

Performance Sports Group Ltd (PSG.TO) (PSG.N), the maker of Bauer ice hockey gear, said on Monday it has filed for bankruptcy protection in the United States and Canada to facilitate a restructuring and sale of almost all of its assets.

3. TeamHealth to be Acquired by Blackstone

KNOXVILLE, Tenn., Oct. 31, 2016 /PRNewswire/ — TeamHealth Holdings, Inc. (“TeamHealth” or the “Company”) (NYSE:…

4. Ophthotech Announces the Publication of Fovista® in Combination with Lucentis® Phase 2b Study Results in Ophthalmology®, the Journal of the American Academy of Ophthalmology

Ophthotech Corporation today announced that the Phase 2b study results of Fovista® , the Company’s anti-PDGF agent administered in combination with Lucentis® anti-VEGF therapy for the treatment of wet age-related macular degeneration , have been published online in Ophthalmology®, the journal of

5. ACADIA Pharmaceuticals Initiates Phase II Study of Pimavanserin in Alzheimer’s Disease Agitation

ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system disorders, today announced the initiation of SERENE, a Phase II study with pimavanserin for the treatment of agitation in patients with Alzheimer’s disease

6. Why After A Massive Run, CoLucid Shares Still Look Attractive

Mirgraine, CoLucid, NASDAQ:CLCD, BioNap, JNapodano, lasmiditan

7. MGM Resorts ready to bet up to $10 billion on Japan casino, possibly via REIT

Las Vegas-based MGM Resorts International (MGM.N) could plow almost $10 billion into a Japanese casino via a publicly traded real estate investment trust, its chief executive said on Monday, as Tokyo inches closer to legalizing the industry.

8. CenturyLink to Buy Level 3 Communications for $25 Billion

CenturyLink Inc. said Monday that it reached a cash-and-stock deal to buy Level 3 Communications Inc. for roughly $25 billion, a marriage that would give the communications companies more heft to weather a competitive landscape.

9. GE Nears Deal to Combine Oil-and-Gas Business With Baker Hughes

General Electric Co. is nearing a roughly $30 billion deal to combine its oil-and-gas business with Baker Hughes Inc., creating an energy powerhouse that would give GE a cost-effective way to play any recovery in the industry.

Technology News